This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against AspenBio Pharma, Inc.

Rigrodsky & Long, P.A. announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired the common stock of AspenBio Pharma, Inc. (“AspenBio Pharma” or the “Company”) (Nasdaq: APPY) between February 22, 2007 and July 19, 2010, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 (the “Complaint”).

The Complaint names AspenBio Pharma and certain of the Company’s current and former executive officers and directors as defendants. AspenBio Pharma is a bio-pharmaceutical company, engaged in the discovery, development, and commercialization of products that address un-met diagnostic and therapeutic needs. Its lead products include AppyScore, a blood-based diagnostic test that evaluates patients suspected of having acute appendicitis for use in diagnosing appendicitis in the hospital emergency department setting.

The Complaint alleges that during the Class Period, defendants made materially false and misleading statements, and/or omitted material facts, concerning the efficacy of AppyScore, which was then undergoing clinical trial. It is alleged that AspenBio claimed that the AppyScore product was: (1) highly effective at detecting patients with a wide spectrum of different severities of appendicitis; (2) utterly unique and unprecedented in its targeted market; (3) extremely helpful in the emergency room context; and (4) able to reduce the incidence of appendicitis related false-positives and unnecessary surgeries.

On July 19, 2010, however, the Company announced that the clinical trial had shown that AppyScore possessed considerably lower specificity than predicted. As a result of these two disclosures, the price of AspenBio Pharma stock first fell from a close of $3.38 on June 4, 2010 to a close of $1.57 on June 7, 2010, and then from a close of $0.97 on July 19, 2010 to a close of $0.69 on July 20, 2010.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,774.25 +96.35 0.58%
S&P 500 1,960.19 +9.37 0.48%
NASDAQ 4,470.2130 +17.4210 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs